Compounds from Natural Products Candidates to Drug for Chikungunya Virus Infection: A Systematic Review.

IF 3 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current drug targets Pub Date : 2024-01-01 DOI:10.2174/0113894501304256240524052446

Larissa de Mattos Oliveira, Janay Stefany Carneiro Araújo, Kaio Vinicius Freitas de Andrade, Ana Tereza Gomes Guerrero Moureau, Manoelito Coelho Dos Santos Junior

{"title":"Compounds from Natural Products Candidates to Drug for Chikungunya Virus Infection: A Systematic Review.","authors":"Larissa de Mattos Oliveira, Janay Stefany Carneiro Araújo, Kaio Vinicius Freitas de Andrade, Ana Tereza Gomes Guerrero Moureau, Manoelito Coelho Dos Santos Junior","doi":"10.2174/0113894501304256240524052446","DOIUrl":null,"url":null,"abstract":"Introduction: Chikungunya fever is a disease caused by infection with the Chikungunya virus, transmitted by Aedes aegypti and Aedes albopictus mosquitoes. Despite its self-limited character, more than 60% of patients have chronic recurrent arthralgia with debilitating pain that lasts for years.Aim: The objective of this review was to gather and analyze evidence from the literature on potential therapeutic strategies with molecules from natural products for the treatment of Chikungunya fever.Methods: A search was performed for clinical trials, observational studies, in vitro or in vivo, without restriction of the year of publication or language in electronic databases (Medline/PubMed, EMBASE, Google Scholar, The Cochrane Library, LILACS (BVS), clinical trial registries (Clinical Trials.gov), digital libraries from CAPES theses and dissertations (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brazil) and conference abstracts. A quality assessment of the selected studies was performed using the SYRCLE, RoB2 and SciRAP tools.Results: 42 studies were included, which showed molecules with potential antiviral pharmacological activity or with activity in reducing the joint complications caused by CHIKV infection.Conclusions: Among the molecules found in the survey of references, regarding the class of secondary metabolites, flavonoids stood out and for this reason, the molecules may be promising candidates for future clinical trials. Overall, evidence from in vitro studies was of acceptable quality; in vivo and intervention studies showed a high risk of bias, which is a limitation of these studies.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"635-648"},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113894501304256240524052446","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Chikungunya fever is a disease caused by infection with the Chikungunya virus, transmitted by Aedes aegypti and Aedes albopictus mosquitoes. Despite its self-limited character, more than 60% of patients have chronic recurrent arthralgia with debilitating pain that lasts for years.

Aim: The objective of this review was to gather and analyze evidence from the literature on potential therapeutic strategies with molecules from natural products for the treatment of Chikungunya fever.

Methods: A search was performed for clinical trials, observational studies, in vitro or in vivo, without restriction of the year of publication or language in electronic databases (Medline/PubMed, EMBASE, Google Scholar, The Cochrane Library, LILACS (BVS), clinical trial registries (Clinical Trials.gov), digital libraries from CAPES theses and dissertations (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brazil) and conference abstracts. A quality assessment of the selected studies was performed using the SYRCLE, RoB2 and SciRAP tools.

Results: 42 studies were included, which showed molecules with potential antiviral pharmacological activity or with activity in reducing the joint complications caused by CHIKV infection.

Conclusions: Among the molecules found in the survey of references, regarding the class of secondary metabolites, flavonoids stood out and for this reason, the molecules may be promising candidates for future clinical trials. Overall, evidence from in vitro studies was of acceptable quality; in vivo and intervention studies showed a high risk of bias, which is a limitation of these studies.

查看原文本刊更多论文

从天然产品候选化合物到治疗基孔肯雅病毒感染的药物：系统综述。

导言基孔肯雅热是一种由埃及伊蚊和白纹伊蚊传播的基孔肯雅病毒感染引起的疾病。尽管基孔肯雅热具有自限性，但超过 60% 的患者会出现慢性复发性关节痛，并伴有持续数年的衰弱性疼痛。目的：本综述旨在从文献中收集和分析利用天然产品分子治疗基孔肯雅热的潜在治疗策略的证据：方法：在电子数据库（Medline/PubMed、EMBASE、Google Scholar、The Cochrane Library、LILACS (BVS)）、临床试验登记处（Clinical Trials.gov）、CAPES论文数字图书馆（Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brazil）和会议摘要中搜索体外或体内临床试验、观察性研究，不限制发表年份或语言。使用 SYRCLE、RoB2 和 SciRAP 工具对所选研究进行了质量评估：结果：共纳入了 42 项研究，这些研究显示了具有潜在抗病毒药理活性或在减少由 CHIKV 感染引起的关节并发症方面具有活性的分子：结论：在参考文献调查中发现的分子中，黄酮类次生代谢物脱颖而出，因此这些分子有可能成为未来临床试验的候选药物。总体而言，体外研究的证据质量尚可；体内研究和干预研究的偏倚风险较高，这也是这些研究的局限性之一。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug targets 医学-药学

CiteScore

6.20

自引率

0.00%

发文量

127

审稿时长

3-8 weeks

期刊介绍： Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.